Diabetes - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols MCM3 and TFAP2B	Name 1 minichromosome maintenance complex component 3	Name2 transcription factor AP-2 beta	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2 SUMOylation of transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors Activation of the TFAP2 (AP-2) family of transcription factors TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Specification of the neural plate border Specification of the neural plate border	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Char syndrome
Novel Novel	Symbols HDAC2 and TREML2	Name 1 histone deacetylase 2	Name2 triggering receptor expressed on myeloid cells like 2	Pathway 1 p75NTR negatively regulates cell cycle via SC1 NOTCH1 Intracellular Domain Regulates Transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants HDACs deacetylate histones Notch-HLH transcription pathway ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression NoRC negatively regulates rRNA expression SUMOylation of chromatin organization proteins Regulation of TP53 Activity through Acetylation RNA Polymerase I Transcription Initiation Regulation of PTEN gene transcription Regulation of PTEN gene transcription Regulation of MECP2 expression and activity MECP2 regulates neuronal receptors and channels FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes EGR2 and SOX10-mediated initiation of Schwann cell myelination EGR2 and SOX10-mediated initiation of Schwann cell myelination Potential therapeutics for SARS STAT3 nuclear events downstream of ALK signaling Negative Regulation of CDH1 Gene Transcription Factors involved in megakaryocyte development and platelet production Regulation of endogenous retroelements by KRAB-ZFP proteins Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)	Pathway 2 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	Drugs 1 Pravastatin Lovastatin Theophylline Valproic acid Valproic acid Simvastatin Atorvastatin Fluvastatin Aminophylline Decitabine Oxtriphylline Vorinostat Vorinostat Belinostat Pracinostat Romidepsin Romidepsin Panobinostat Phenylbutyric acid Tixocortol Mocetinostat Entinostat Abexinostat Givinostat Pyroxamide	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols EXOSC8 and RERG	Name 1 exosome component 8	Name2 RAS like estrogen regulated growth inhibitor	Pathway 1 ATF4 activates genes in response to endoplasmic reticulum stress mRNA decay by 3' to 5' exoribonuclease Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA Major pathway of rRNA processing in the nucleolus and cytosol Nuclear RNA decay	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FGFR3 and STK32B	Name 1 fibroblast growth factor receptor 3	Name2 serine/threonine kinase 32B	Pathway 1 Signaling by activated point mutants of FGFR3 t(4;14) translocations of FGFR3 Signaling by FGFR3 in disease Signaling by FGFR3 fusions in cancer	Pathway 2	Drugs 1 XL999 Pazopanib Ponatinib Lenvatinib Nintedanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib	Drugs 2	Diseases 1 CATSHL syndrome Multiple myeloma FGFR3-related short limb skeletal dysplasias, including: Achondroplasia; Hypochondroplasia; Thanatophoric dysplasia, type 1; Thanatophoric dysplasia, type 2; Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Bladder cancer	Diseases 2
Novel Novel	Symbols HOXA1 and ITGB8	Name 1 homeobox A1	Name2 integrin subunit beta 8	Pathway 1 Activation of anterior HOX genes in hindbrain development during early embryogenesis	Pathway 2 Molecules associated with elastic fibres Integrin cell surface interactions TGF-beta receptor signaling activates SMADs	Drugs 1	Drugs 2	Diseases 1 Bosley-Salih-Alorainy syndrome and Athabascan brainstem dysgenesis syndrome	Diseases 2
Novel Novel	Symbols TRIM32 and ASTN2	Name 1 tripartite motif containing 32	Name2 astrotactin 2	Pathway 1 Regulation of innate immune responses to cytosolic DNA Antigen processing: Ubiquitination & Proteasome degradation	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Bardet-Biedl syndrome (BBS)	Diseases 2
Novel Novel	Symbols RAB3IL1 and FADS2	Name 1 RAB3A interacting protein like 1	Name2 fatty acid desaturase 2	Pathway 1 RAB GEFs exchange GTP for GDP on RABs	Pathway 2 Linoleic acid (LA) metabolism alpha-linolenic acid (ALA) metabolism alpha-linolenic acid (ALA) metabolism	Drugs 1	Drugs 2 alpha-Linolenic acid	Diseases 1	Diseases 2
Novel Novel	Symbols HOOK1 and MYSM1	Name 1 hook microtubule tethering protein 1	Name2 Myb like, SWIRM and MPN domains 1	Pathway 1	Pathway 2 Metalloprotease DUBs	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols HOOK1 and ERI3	Name 1 hook microtubule tethering protein 1	Name2 ERI1 exoribonuclease family member 3	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CCND2 and ARID5B	Name 1 cyclin D2	Name2 AT-rich interaction domain 5B	Pathway 1 Cyclin D associated events in G1 Regulation of RUNX1 Expression and Activity Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity	Pathway 2 HDMs demethylate histones	Drugs 1	Drugs 2	Diseases 1 Testicular cancer	Diseases 2
Novel Novel	Symbols CTH and PTGFR	Name 1 cystathionine gamma-lyase	Name2 prostaglandin F receptor	Pathway 1 Degradation of cysteine and homocysteine Cysteine formation from homocysteine Metabolism of ingested SeMet, Sec, MeSec into H2Se	Pathway 2 Prostanoid ligand receptors G alpha (q) signalling events	Drugs 1 Pyridoxal phosphate Cysteine 2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Imino]-5-Phosphono-Pent-3-Enoic Acid Carboxymethylthio-3-(3-Chlorophenyl)-1,2,4-Oxadiazol L-2-amino-3-butynoic acid	Drugs 2 Travoprost Latanoprost Bimatoprost Dinoprost tromethamine Tafluprost Latanoprostene bunod	Diseases 1 Cystathioninuria	Diseases 2
Novel Novel	Symbols CDKN2B and ELAVL2	Name 1 cyclin dependent kinase inhibitor 2B	Name2 ELAV like RNA binding protein 2	Pathway 1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Type II diabetes mellitus Osteosarcoma Malignant pleural mesothelioma	Diseases 2
Novel Novel	Symbols DTNBP1 and HDGFL1	Name 1 dystrobrevin binding protein 1	Name2 HDGF like 1	Pathway 1 Golgi Associated Vesicle Biogenesis	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Hermansky-Pudlak syndrome (HPS)	Diseases 2
Novel Novel	Symbols TRAF6 and RPP21	Name 1 TNF receptor associated factor 6	Name2 ribonuclease P subunit p21	Pathway 1 PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment Regulated proteolysis of p75NTR Downstream TCR signaling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes NF-kB is activated and signals survival FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 CLEC7A (Dectin-1) signaling Ub-specific processing proteases Ovarian tumor domain proteases PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TICAM1,TRAF6-dependent induction of TAK1 complex Interleukin-1 signaling TRAF6 mediated IRF7 activation TRAF6 mediated NF-kB activation TRAF6 mediated NF-kB activation IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 IRAK2 mediated activation of TAK1 complex TRAF6-mediated induction of TAK1 complex within TLR4 complex Alpha-protein kinase 1 signaling pathway SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation MyD88 dependent cascade initiated on endosome IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation Regulation of NF-kappa B signaling MyD88 cascade initiated on plasma membrane	Pathway 2 tRNA processing in the nucleus Major pathway of rRNA processing in the nucleolus and cytosol	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols PPP2CB and ICOSLG	Name 1 protein phosphatase 2 catalytic subunit beta	Name2 inducible T cell costimulator ligand	Pathway 1 Inhibition of replication initiation of damaged DNA by RB1/E2F1 Spry regulation of FGF signaling Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal PP2A-mediated dephosphorylation of key metabolic factors DARPP-32 events Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade ERK/MAPK targets ERKs are inactivated MASTL Facilitates Mitotic Progression Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion Co-stimulation by CD28 Co-inhibition by CTLA4 Platelet sensitization by LDL Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex RHO GTPases Activate Formins RAF activation Negative regulation of MAPK pathway Regulation of TP53 Degradation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Mitotic Prometaphase Cyclin D associated events in G1 Cyclin A/B1/B2 associated events during G2/M transition Regulation of glycolysis by fructose 2,6-bisphosphate metabolism EML4 and NUDC in mitotic spindle formation PKR-mediated signaling	Pathway 2 Co-stimulation by ICOS	Drugs 1 Vitamin E	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CPVL and -	Name 1 carboxypeptidase vitellogenic like	Name2 TCR gamma alternate reading frame protein	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DEDD and VPS26A	Name 1 death effector domain containing	Name2 VPS26 retromer complex component A	Pathway 1	Pathway 2 WNT ligand biogenesis and trafficking	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols SHMT2 and COMMD6	Name 1 serine hydroxymethyltransferase 2	Name2 COMM domain containing 6	Pathway 1 Metabolism of folate and pterines RHOG GTPase cycle Mitochondrial protein degradation	Pathway 2 Neddylation	Drugs 1 Pyridoxal phosphate Tetrahydrofolic acid Glycine Artenimol	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TNF and TNXB	Name 1 tumor necrosis factor	Name2 tenascin XB	Pathway 1 Transcriptional regulation of white adipocyte differentiation TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production TNFR2 non-canonical NF-kB pathway Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling TNF signaling Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)	Pathway 2 ECM proteoglycans	Drugs 1 Etanercept Adalimumab Infliximab Chloroquine Epinephrine Pseudoephedrine Clenbuterol Pranlukast Amrinone Trichostatin A Afelimomab YSIL6 SD118 PN0621 OMS-103HP Talmapimod VX-702 Atiprimod CRx-139 CYT007-TNFQb Andrographolide Ethyl pyruvate AME-527 PR-104 Plinabulin Dexanabinol Onercept Golimumab Certolizumab pegol Pomalidomide Polaprezinc Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Bryostatin 1 Binimetinib Dilmapimod Glycyrrhizic acid	Drugs 2	Diseases 1 Graft-versus-host disease Systemic lupus erythematosus Allograft rejection Asthma	Diseases 2 Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
Novel Novel	Symbols PSEN1 and LRRC74A	Name 1 presenilin 1	Name2 leucine rich repeat containing 74A	Pathway 1 Nuclear signaling by ERBB4 Degradation of the extracellular matrix Regulated proteolysis of p75NTR NRIF signals cell death from the nucleus Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus EPH-ephrin mediated repulsion of cells Neutrophil degranulation NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH4 Activation and Transmission of Signal to the Nucleus Noncanonical activation of NOTCH3 TGFBR3 PTM regulation	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Alzheimer's disease (AD) Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3) Acne inversa; Hidradenitis supprativa	Diseases 2
Novel	Symbols MCM3 and TFAP2B	Name 1 minichromosome maintenance complex component 3	Name2 transcription factor AP-2 beta	Pathway 1 Activation of ATR in response to replication stress Unwinding of DNA Assembly of the pre-replicative complex Assembly of the pre-replicative complex Orc1 removal from chromatin Activation of the pre-replicative complex Switching of origins to a post-replicative state	Pathway 2 SUMOylation of transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors Negative regulation of activity of TFAP2 (AP-2) family transcription factors Activation of the TFAP2 (AP-2) family of transcription factors TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Specification of the neural plate border Specification of the neural plate border	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Char syndrome
Novel	Symbols HDAC2 and TREML2	Name 1 histone deacetylase 2	Name2 triggering receptor expressed on myeloid cells like 2	Pathway 1 p75NTR negatively regulates cell cycle via SC1 NOTCH1 Intracellular Domain Regulates Transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants HDACs deacetylate histones Notch-HLH transcription pathway ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression NoRC negatively regulates rRNA expression SUMOylation of chromatin organization proteins Regulation of TP53 Activity through Acetylation RNA Polymerase I Transcription Initiation Regulation of PTEN gene transcription Regulation of PTEN gene transcription Regulation of MECP2 expression and activity MECP2 regulates neuronal receptors and channels FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes EGR2 and SOX10-mediated initiation of Schwann cell myelination EGR2 and SOX10-mediated initiation of Schwann cell myelination Potential therapeutics for SARS STAT3 nuclear events downstream of ALK signaling Negative Regulation of CDH1 Gene Transcription Factors involved in megakaryocyte development and platelet production Regulation of endogenous retroelements by KRAB-ZFP proteins Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)	Pathway 2 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	Drugs 1 Pravastatin Lovastatin Theophylline Valproic acid Valproic acid Simvastatin Atorvastatin Fluvastatin Aminophylline Decitabine Oxtriphylline Vorinostat Vorinostat Belinostat Pracinostat Romidepsin Romidepsin Panobinostat Phenylbutyric acid Tixocortol Mocetinostat Entinostat Abexinostat Givinostat Pyroxamide	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols EXOSC8 and RERG	Name 1 exosome component 8	Name2 RAS like estrogen regulated growth inhibitor	Pathway 1 ATF4 activates genes in response to endoplasmic reticulum stress mRNA decay by 3' to 5' exoribonuclease Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA Major pathway of rRNA processing in the nucleolus and cytosol Nuclear RNA decay	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FGFR3 and STK32B	Name 1 fibroblast growth factor receptor 3	Name2 serine/threonine kinase 32B	Pathway 1 Signaling by activated point mutants of FGFR3 t(4;14) translocations of FGFR3 Signaling by FGFR3 in disease Signaling by FGFR3 fusions in cancer	Pathway 2	Drugs 1 XL999 Pazopanib Ponatinib Lenvatinib Nintedanib Infigratinib Fostamatinib Erdafitinib Pemigatinib Futibatinib Selpercatinib	Drugs 2	Diseases 1 CATSHL syndrome Multiple myeloma FGFR3-related short limb skeletal dysplasias, including: Achondroplasia; Hypochondroplasia; Thanatophoric dysplasia, type 1; Thanatophoric dysplasia, type 2; Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Bladder cancer	Diseases 2
Novel	Symbols HOXA1 and ITGB8	Name 1 homeobox A1	Name2 integrin subunit beta 8	Pathway 1 Activation of anterior HOX genes in hindbrain development during early embryogenesis	Pathway 2 Molecules associated with elastic fibres Integrin cell surface interactions TGF-beta receptor signaling activates SMADs	Drugs 1	Drugs 2	Diseases 1 Bosley-Salih-Alorainy syndrome and Athabascan brainstem dysgenesis syndrome	Diseases 2
Novel	Symbols TRIM32 and ASTN2	Name 1 tripartite motif containing 32	Name2 astrotactin 2	Pathway 1 Regulation of innate immune responses to cytosolic DNA Antigen processing: Ubiquitination & Proteasome degradation	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Bardet-Biedl syndrome (BBS)	Diseases 2
Novel	Symbols RAB3IL1 and FADS2	Name 1 RAB3A interacting protein like 1	Name2 fatty acid desaturase 2	Pathway 1 RAB GEFs exchange GTP for GDP on RABs	Pathway 2 Linoleic acid (LA) metabolism alpha-linolenic acid (ALA) metabolism alpha-linolenic acid (ALA) metabolism	Drugs 1	Drugs 2 alpha-Linolenic acid	Diseases 1	Diseases 2
Novel	Symbols HOOK1 and MYSM1	Name 1 hook microtubule tethering protein 1	Name2 Myb like, SWIRM and MPN domains 1	Pathway 1	Pathway 2 Metalloprotease DUBs	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols HOOK1 and ERI3	Name 1 hook microtubule tethering protein 1	Name2 ERI1 exoribonuclease family member 3	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CCND2 and ARID5B	Name 1 cyclin D2	Name2 AT-rich interaction domain 5B	Pathway 1 Cyclin D associated events in G1 Regulation of RUNX1 Expression and Activity Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity	Pathway 2 HDMs demethylate histones	Drugs 1	Drugs 2	Diseases 1 Testicular cancer	Diseases 2
Novel	Symbols CTH and PTGFR	Name 1 cystathionine gamma-lyase	Name2 prostaglandin F receptor	Pathway 1 Degradation of cysteine and homocysteine Cysteine formation from homocysteine Metabolism of ingested SeMet, Sec, MeSec into H2Se	Pathway 2 Prostanoid ligand receptors G alpha (q) signalling events	Drugs 1 Pyridoxal phosphate Cysteine 2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Imino]-5-Phosphono-Pent-3-Enoic Acid Carboxymethylthio-3-(3-Chlorophenyl)-1,2,4-Oxadiazol L-2-amino-3-butynoic acid	Drugs 2 Travoprost Latanoprost Bimatoprost Dinoprost tromethamine Tafluprost Latanoprostene bunod	Diseases 1 Cystathioninuria	Diseases 2
Novel	Symbols CDKN2B and ELAVL2	Name 1 cyclin dependent kinase inhibitor 2B	Name2 ELAV like RNA binding protein 2	Pathway 1 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Type II diabetes mellitus Osteosarcoma Malignant pleural mesothelioma	Diseases 2
Novel	Symbols DTNBP1 and HDGFL1	Name 1 dystrobrevin binding protein 1	Name2 HDGF like 1	Pathway 1 Golgi Associated Vesicle Biogenesis	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Hermansky-Pudlak syndrome (HPS)	Diseases 2
Novel	Symbols TRAF6 and RPP21	Name 1 TNF receptor associated factor 6	Name2 ribonuclease P subunit p21	Pathway 1 PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment Regulated proteolysis of p75NTR Downstream TCR signaling NRIF signals cell death from the nucleus NRIF signals cell death from the nucleus p75NTR recruits signalling complexes NF-kB is activated and signals survival FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 CLEC7A (Dectin-1) signaling Ub-specific processing proteases Ovarian tumor domain proteases PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TICAM1,TRAF6-dependent induction of TAK1 complex Interleukin-1 signaling TRAF6 mediated IRF7 activation TRAF6 mediated NF-kB activation TRAF6 mediated NF-kB activation IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 IRAK2 mediated activation of TAK1 complex TRAF6-mediated induction of TAK1 complex within TLR4 complex Alpha-protein kinase 1 signaling pathway SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation MyD88 dependent cascade initiated on endosome IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation Regulation of NF-kappa B signaling MyD88 cascade initiated on plasma membrane	Pathway 2 tRNA processing in the nucleus Major pathway of rRNA processing in the nucleolus and cytosol	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols PPP2CB and ICOSLG	Name 1 protein phosphatase 2 catalytic subunit beta	Name2 inducible T cell costimulator ligand	Pathway 1 Inhibition of replication initiation of damaged DNA by RB1/E2F1 Spry regulation of FGF signaling Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal PP2A-mediated dephosphorylation of key metabolic factors DARPP-32 events Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade ERK/MAPK targets ERKs are inactivated MASTL Facilitates Mitotic Progression Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion Co-stimulation by CD28 Co-inhibition by CTLA4 Platelet sensitization by LDL Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex RHO GTPases Activate Formins RAF activation Negative regulation of MAPK pathway Regulation of TP53 Degradation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Mitotic Prometaphase Cyclin D associated events in G1 Cyclin A/B1/B2 associated events during G2/M transition Regulation of glycolysis by fructose 2,6-bisphosphate metabolism EML4 and NUDC in mitotic spindle formation PKR-mediated signaling	Pathway 2 Co-stimulation by ICOS	Drugs 1 Vitamin E	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CPVL and -	Name 1 carboxypeptidase vitellogenic like	Name2 TCR gamma alternate reading frame protein	Pathway 1	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DEDD and VPS26A	Name 1 death effector domain containing	Name2 VPS26 retromer complex component A	Pathway 1	Pathway 2 WNT ligand biogenesis and trafficking	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols SHMT2 and COMMD6	Name 1 serine hydroxymethyltransferase 2	Name2 COMM domain containing 6	Pathway 1 Metabolism of folate and pterines RHOG GTPase cycle Mitochondrial protein degradation	Pathway 2 Neddylation	Drugs 1 Pyridoxal phosphate Tetrahydrofolic acid Glycine Artenimol	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TNF and TNXB	Name 1 tumor necrosis factor	Name2 tenascin XB	Pathway 1 Transcriptional regulation of white adipocyte differentiation TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production TNFR2 non-canonical NF-kB pathway Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling TNF signaling Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)	Pathway 2 ECM proteoglycans	Drugs 1 Etanercept Adalimumab Infliximab Chloroquine Epinephrine Pseudoephedrine Clenbuterol Pranlukast Amrinone Trichostatin A Afelimomab YSIL6 SD118 PN0621 OMS-103HP Talmapimod VX-702 Atiprimod CRx-139 CYT007-TNFQb Andrographolide Ethyl pyruvate AME-527 PR-104 Plinabulin Dexanabinol Onercept Golimumab Certolizumab pegol Pomalidomide Polaprezinc Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Bryostatin 1 Binimetinib Dilmapimod Glycyrrhizic acid	Drugs 2	Diseases 1 Graft-versus-host disease Systemic lupus erythematosus Allograft rejection Asthma	Diseases 2 Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
Novel	Symbols PSEN1 and LRRC74A	Name 1 presenilin 1	Name2 leucine rich repeat containing 74A	Pathway 1 Nuclear signaling by ERBB4 Degradation of the extracellular matrix Regulated proteolysis of p75NTR NRIF signals cell death from the nucleus Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants NOTCH2 Activation and Transmission of Signal to the Nucleus EPH-ephrin mediated repulsion of cells Neutrophil degranulation NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH4 Activation and Transmission of Signal to the Nucleus Noncanonical activation of NOTCH3 TGFBR3 PTM regulation	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Alzheimer's disease (AD) Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3) Acne inversa; Hidradenitis supprativa	Diseases 2

Page 2 out of 58 pages

Search Results : Diabetes